paracetamol and dihydrocodeine
paracetamol and dihydrocodeine
CLINICAL USE
Analgesic
DOSE IN NORMAL RENAL FUNCTION
1–2 tablets up to 4 times a day
PHARMACOKINETICS
Molecular weight                           :Paracetamol: 151.2; dihydrocodeine: 451.5 (as tartrate) %Protein binding                           :Paracetamol: 20–30; dihydrocodeine: – %Excreted unchanged in urine     : Paracetamol: <5; dihydrocodeine: 13–22 Volume of distribution (L/kg)       :Paracetamol: 1–2; dihydrocodeine: 1.1half-life – normal/ESRD (hrs)      :Paracetamol: 1–4/Unchanged; dihydrocodeine: 3.5–5/6+ DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : 50–100% of dose every 6 hours <10           : 50–100% of dose every 6–8 hours DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Dose as in GFR <10 mL/min HD                     :Not dialysed. Dose as in GFR <10 mL/min HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/minCAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Active metabolites of dihydrocodeine accumulate in renal impairment (drowsiness/lightheadedness/constipation). Increased cerebral sensitivity in patients with renal failureCo-dydramol
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home